Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment

Giacomo Cafaro1†, Eleonora Petito2†, Onelia Bistoni1, Emanuela Falcinelli2, Sabrina Cipriani1, Maria Chiara Borghi2, Angelo F. Bonifacio1, Elisa Giglio2, Alessia Alunno1,3, Carlo Perricone1, Roberto Gerli1*, Paolo Gresele2† and Elena Bartoloni1†

Abstract

Background: Endothelial dysfunction contributes to increased cardiovascular (CV) disease in rheumatoid arthritis (RA). Angiogenic T cells (Tang) are a key regulator of vascular function via their interaction with endothelial progenitor cells (EPCs). Methotrexate (MTX) has been associated to reduced CV disease risk, but its effects on endothelial homeostasis have been poorly explored. We investigated MTX effects on endothelial homeostasis in early, treatment-naïve RA patients.

Methods: Fifteen untreated, early RA patients and matched healthy controls (HC) were enrolled. RA patients with long-standing disease in remission or low disease activity treated with MTX for at least 6 months were selected as controls. Circulating CD28+ and CD28null Tang cell, endothelial microparticle (EMP), EPC and soluble vascular cell adhesion molecule (sVCAM)-1 levels were measured.

Results: Tang percentage was higher in early RA than in HCs and significantly increased after 3-month MTX treatment. Tang cells in RA were characterized by higher percentage of CD28null and lower CD28-positive cells than HCs. MTX restored a Tang cell phenotype similar to HCs. Altered sVCAM-1, EMP and EPC were restored to levels similar to HCs after a 3-month MTX. Biomarker levels after 3 months of MTX were not different to those of patients with long-standing treatment.

Conclusions: MTX has a positive effect on Tang, sVCAM-1, EPCs and EMPs in RA. Restoration of imbalance between CD28+ and CD28null Tang by MTX may be one of the mechanisms underlying its favourable effects on endothelial dysfunction. These effects seem to be long-lasting and independent from systemic inflammation reduction, suggesting a direct effect of MTX on the endothelium.

Keywords: Methotrexate, Rheumatoid arthritis, Endothelial dysfunction, Cardiovascular disease, Angiogenic T cells, Platelets, Microvesicles

Background

Physiologic endothelial function is maintained thanks to a complex network of damage restoration mechanisms to which several molecules as well as cellular populations contribute [1]. Loss of endothelial layer integrity and function represents one of the earliest triggers of atherosclerosis and a pivotal mechanism contributing
to the increased risk of cardiovascular (CV) disease in patients with chronic inflammatory disorders, including rheumatoid arthritis (RA) [2–8]. In this setting, inflammatory and immune-mediated mechanisms are still incompletely understood and interact with traditional CV risk factors in the induction and perpetuation of endothelial damage, thus contributing to CV risk [8, 9]. A key player of endothelial dysfunction is platelet CD40L, a type II transmembrane protein belonging to the tumour necrosis factor (TNF) superfamily expressed on the surface of activated platelets, which induces endothelial cell activation interacting with CD40, inducing an increase in vascular cell adhesion molecule-1 (VCAM-1) expression [10] and favouring atherosclerosis progression and increased CV risk [11–13]. In patients with systemic autoimmune diseases, an increase in circulating endothelial microparticles (EMPs) in association with progressive exhaustion of endothelial progenitor cells (EPCs) has been associated with endothelial damage and with defective vascular layer restoration [14, 15]. A specific T cell population, characterized by the co-expression of CD3, CD31 and CXCR4 and termed angiogenic T cells (Tang), has recently emerged as a key regulator of vascular function and neo-angiogenesis due to their interaction with EPCs [16]. Of note, altered levels of circulating Tang cells and of their senescent CD28null phenotype have been demonstrated to correlate with endothelial damage and adverse CV outcome in patients with systemic lupus erythematosus (SLE), RA and primary Sjögren’s syndrome (pSS) [17–20]. In these patients, as well as in subjects with increased CV risks such as hypertension and diabetes mellitus, Tang cells correlate with circulating EPCs and mainly exhibit an immunosenescent, pro-inflammatory and cytotoxic profile, suggesting their role as a reliable marker of accelerated atherosclerosis and endothelial dysfunction [17, 18, 21, 22].

The possible ability of drugs to improve these cellular biomarkers may help to identify new pharmacological strategies to prevent or reduce endothelial dysfunction. Methotrexate (MTX) represents the gold standard and first-line drug in the treatment of RA patients interfering with multiple inflammatory and metabolic pathways, such as homocysteine and nucleic acid metabolism [23]. Interestingly, long-term MTX therapy has been also associated with a 28% overall lower risk of major CV events, in particular, myocardial infarction, a 57% reduction of hospitalization for heart failure and with reduced CV mortality in RA patients [24, 25]. This probably reflects the reduction of the systemic inflammatory burden by MTX treatment, with a consequent decrease in atherosclerotic CV risk. Moreover, although with some conflicting evidence, improvement of arterial stiffness, endothelial dysfunction and carotid intima-media thickness, as well as of insulin resistance and lipid pro-atherogenic profile, has been observed in MTX-treated RA patients [26, 27]. In vitro and ex vivo studies, as well as in vivo experiments in mouse models of atherogenesis, have shown that MTX may exert direct anti-inflammatory and protective effects on endothelial layer and function. In particular, increased intracellular levels of adenosine by activation of adenosine monophosphate-protein kinase genes, reduction of inflammatory cytokines and oxidative stress, scavenging of free radicals and inhibition of neutrophil oxidative burst, as well as improvement of aortic thickening by acting on over-expression of endothelial cell beta-3 receptors, have been suggested as potential mechanisms in recent studies [28–32]. Interestingly, a significant reduction of serum syndecan-1 levels, reflecting an improvement of endothelial layer integrity, was observed following a 6-week MTX monotherapy in a small cohort of RA patients [33]. Taken together, these results suggest a protective, anti-inflammatory activity of MTX on endothelial layer integrity and function. However, the positive effect on endothelial homeostasis and the reduced risk of CV events in RA seem to be partly independent from MTX-induced improvement of disease activity, suggesting that alternative mechanisms may contribute to the improvement of endothelial function and reduction of CV risk [24, 33]. The effect of MTX on biomarkers and cell subsets of endothelial damage and repair has been poorly explored. In particular, no studies evaluated the behaviour of Tang and immunosenescent CD28null lymphocytes following MTX administration in patients with inflammatory rheumatic diseases. Thus, the aim of the present study was to investigate the effects of the 3-month MTX treatment on biomarkers of endothelial homeostasis in a cohort of treatment-naïve RA patients by evaluating the changes in circulating Tang cells and their subpopulations, sVCAM, PMPs, platelet CD40L, EPCs and CECs.

**Methods**

**Patients**

Consecutive, untreated, early (≤3 months from symptom onset) RA patients with moderately-highly active defined as Disease Activity Score on 28 joints (DAS28) based on C-reactive protein (DAS28-CRP) ≥ 3.2 and age- and sex-matched healthy controls (HC) were enrolled between April 2018 and June 2019. A cohort of age- and sex-matched RA patients with long-standing disease in remission or low disease activity (DAS28 <3.2) treated with MTX for at least 6 months was also selected as additional comparators. All RA patients fulfilled the 2010 ACR/EULAR classification criteria [34]. To avoid the risk of bias due to the presence of other factors with a potential influence on the markers under investigation,
patients with a history of major CV disease (acute myocardial infarction, transient ischemic attacks, stroke, clinically relevant arrhythmia, peripheral artery disease, congestive heart failure), taking anti-platelet or anti-coagulant agents, prednisone > 10 mg/die or who had taken non-steroidal anti-inflammatory drugs in the previous 7 days were excluded. No other disease-modifying anti-rheumatic drugs, nor hydroxychloroquine, were allowed. All patients underwent a detailed medical interview and clinical examination. For the purpose of the study, the following parameters were specifically collected: anthropometric measures (height, weight, body mass index), smoking status (current, former, never) and history of diabetes mellitus, dyslipidaemia and hypertension. Diabetes mellitus was defined by a fasting glucose of ≥126 mg/dL or the use of antidiabetic drugs. Hypertension was defined as a previous physician's diagnosis or current anti-hypertensive treatment. Hypercholesterolaemia and hypertriglyceridaemia were defined as previous diagnosis or need for treatment as defined by the ESC/EAS Guidelines for the management of dyslipidaemias [35]. The 10-year risk of CV disease was calculated by the Q-RISK2 score as the Q-RISK3 score was not yet validated when the study was designed and approved [36]. Disease-related parameters were also recorded in all patients and included the following: tender joint count (TJC), swollen joint count (SJC), patient's global assessment (PGA), physician's global assessment (PhGA), CRP and erythrocyte sedimentation rate (ESR). Disease activity was calculated by DAS28 with both CRP and ESR, clinical disease activity index (CDAI) and simplified disease activity index (SDAI).

Study procedures were collected in early RA patients before and 3 months after the introduction of MTX treatment.

The study was conducted according to the guidelines of the Declaration of Helsinki. The protocol was approved by the local ethics committee Comitato Etico Regionale Umbria, 3110/17. All subjects provided written informed consent.

**Angiogenic T cells**

Peripheral blood was collected in lithium-heparin tubes, and PBMCs were isolated by gradient using Lymphoprep (Stemcell Technologies, Vancouver, Canada) according to the manufacturer’s instructions. Staining with anti-CD4, anti-CD31, anti-CXCR4 and anti-CD28 antibodies (Becton, Dickinson and Company, NJ, USA) was performed, and data were acquired with BD FACS Calibur (Becton, Dickinson and Company, NJ, USA) flow cytometer and analysed with BD CellQuest Pro software (Becton, Dickinson and Company, NJ, USA).

**Endothelial activation markers**

As endothelial activation markers, we assessed soluble VCAM-1 (sVCAM-1) by ELISA, endothelial-derived extracellular microvesicles (EVs), circulating endothelial cells (CECs) and circulating endothelial progenitor cells (EPCs) by flow cytometry, as previously reported [3, 4, 37].

Plasma levels of sVCAM-1 were measured by ELISA (R&D system, Abingdon, UK), as described [37]. The intra-assay coefficient of variation for sVCAM-1 was 3.1%, and the interassay coefficient of variation was 7%. The results are reported as ng/mL.

Endothelial-derived extracellular microvesicles (EVs) were assessed by flow cytometry. Citrated plasma was centrifuged at 12,000 × g for 2 min to obtain platelet-free plasma (PFP). Fifty microlitres of PFP was incubated with an anti-CD146-PE-labelled antibody, an endothelial junctional cell adhesion molecule (CAM) belonging to the immunoglobulin superfamily, or with the isotype control antibody (all from Beckman Coulter, Miami, FL, USA). After 30 min at room temperature in the dark, the reaction was stopped with PBS. The microvesicle morphological gate was set using Megamix (BioCytex, Marseille, France), a mix of fluorescent beads of various diameters covering the microvesicle size range of 0.1 to 1 μm. To quantify EVs, 50 μL of a known concentration of Flow Count Coulter fluorospheres (Beckman Coulter, Miami, FL, USA) was added to the FACS tubes prior to analysis. The results are reported as microvesicle number per microliter (EVs/μL) [4].

Circulating CECs and EPCs were identified and characterized in the whole blood collected in 0.18% K3EDTA by flow cytometry (Cytoflex, Beckman Coulter, Miami, FL, USA) using progenitor, haematopoietic and endothelial markers. For the identification of CECs, a combination of CD45, CD31 and CD146 was used, while for the identification of circulating EPCs, antibodies against human CD45, CD34 and CD309 (Beckman Coulter, Miami, FL, USA) were used. Briefly, 10 μL of each fluorescence-labelled antibody was added to 100 μL of whole blood then incubated in the dark at room temperature for 30 min; 2 mL of red cell lysing solution was added, and the tube was incubated for 15 min at room temperature, prior to sample reading. To quantify cells, 100 μL of a known concentration of Flow Count Coulter fluorospheres was added to the FACS tubes just prior to analysis. The results were expressed as absolute cell number per microliter [4].

**Surface platelet activation markers**

Venous whole blood was collected in trisodium citrate 3.2% (0.109 M, 1/10 v/v), and platelet CD40L was
assessed by flow cytometry (CytoFLEX, Beckman Coulter, Miami, FL, USA) as previously reported [2]. Five microlitres of whole blood was incubated with saturating concentrations of anti-CD41 [platelet GPIIb]-fluorescein isothiocyanate (FITC)-labelled and anti-CD40L-phycocerythrin (PE)-labelled or isotype control antibody (IgG PE-labelled antibody) (all from Beckman Coulter, Miami, FL, USA). After 30 min of incubation in the dark, samples were diluted with PBS and analysed. The results are reported as the percentage of CD40L-positive platelets.

**Data analysis**

Sample size calculation was not performed due to the absence of previous data and the pilot nature of the study. Continuous variables were analysed with the Wilcoxon signed-rank test (paired samples) or the Mann–Whitney U test (unpaired samples). Categorical variables were analysed with the \( \chi^2 \) test or Fisher’s exact test, as appropriate. Correlations were analysed with the Spearman test. Data are considered significant for \( p \leq 0.05 \). Samples with missing data were excluded sample-wise. All the analysis was performed with IBM SPSS Statistics v.26 (IBM Corp. Armonk, NY, USA). Plots were designed with GraphPad Prism version 8.0.0 (GraphPad Software, San Diego, CA, USA). Data are shown as mean ± standard error of the mean or absolute number and percentage.

**Results**

**Participants’ characteristics**

Fifteen patients with early RA and 15 age- and sex-matched HC were enrolled. At follow-up, one RA patient was excluded as treatment with acetylsalicylic acid was introduced after enrollment. Demographic features and traditional CV risk factors in both cohorts are shown in Table 1. Prevalence of current and former smoking habit and QRISK-2 score were significantly higher in RA patients as compared to HCs. The prevalence of hypertension, diabetes mellitus, hypercholesterolaemia and hypertriglyceridaemia was similar between the two groups. At baseline, RA patients were characterized by moderate-high disease activity according to SDAI, CDAI and DAS28-CRP scores. Disease activity significantly

| Characteristic | Control group (HC), \( n = 15 \) | Early RA (RA), \( n = 15 \) | \( p \) (HC vs RA) | MTX at 3 months (RA MTX T1), \( n = 14 \) | \( p \) (MTX 3 months vs RA) |
|---------------|--------------------------------|------------------------------|------------------|--------------------------------|------------------|
| Age           | 53.3 ± 7.03                   | 60 ± 8.06                    | 0.25             |                                |                  |
| Sex (n, %F)   | 11 (73.3%)                    | 11 (73.3%)                   | 1.0              |                                |                  |
| Smoking habit |                               |                              | \( 0.038 \)      |                                |                  |
| Never smoker  | 11 (73.3%)                    | 4 (26.7%)                    |                  |                                |                  |
| Current smoker| 2 (13.3%)                     | 6 (40.0%)                    |                  |                                |                  |
| Former smoker | 2 (13.3%)                     | 5 (33.3%)                    |                  |                                |                  |
| RF (n, %)     | 10 (66.7%)                    | 11 (73.3%)                   |                  |                                |                  |
| ACPA (n, %)   | 11 (73.3%)                    |                              |                  |                                |                  |
| TJC           | 4.2 ± 7.0                     | 3.1 ± 2.3                    | \( 0.041 \)      |                                |                  |
| SJC           | 3.1 ± 1.8                     | 0.9 ± 1.1                    | \( 0.031 \)      |                                |                  |
| CRP (mg/dl)   | 1.89 ± 1.36                   | 0.92 ± 0.68                  | \( 0.234 \)      |                                |                  |
| ESR           | 26.6 ± 13.1                   | 20.4 ± 10.4                  | \( 0.591 \)      |                                |                  |
| PGA           | 64 ± 1.2                      | 3.4 ± 1.4                    | \( 0.063 \)      |                                |                  |
| PhGA          | 4.6 ± 0.9                     | 2.5 ± 1.2                    | \( 0.046 \)      |                                |                  |
| DAS28-CRP     | 4.61 ± 0.51                   | 2.96 ± 0.7                   | \( 0.016 \)      |                                |                  |
| DAS28-ESR     | 4.49 ± 0.72                   | 3.15 ± 0.82                  | \( 0.085 \)      |                                |                  |
| SDAI          | 23.3 ± 5.53                   | 10.8 ± 5.8                   | \( 0.026 \)      |                                |                  |
| CDAI          | 21.4 ± 5.1                    | 9.9 ± 10.3                   | \( 0.051 \)      |                                |                  |
| MTX dose      | 11.4 ± 0.8                    |                              |                  |                                |                  |
| BMI           | 25.1 ± 1.8                    | 24.7 ± 1.7                   | \( 0.902 \)      |                                |                  |
| QRISK-2 score | 7.9 ± 10.2                    | 18.9 ± 16.3                  | \( 0.029 \)      |                                |                  |
| Hypertension  | 4 (26.7%)                     | 5 (33.3%)                    | 0.5              |                                |                  |
| Diabetes mellitus | 0                          | 0                             | 1.0              |                                |                  |
| Hypercholesterolaemia | 4 (26.7%) | 7 (46.7%)                  | \( 0.449 \)      |                                |                  |
| Hypertriglyceridaemia | 2 (13.3%) | 3 (20.0%)                  | 0.5              |                                |                  |

Data are shown as mean ± standard error or number (percentage)
improved after 3 months of MTX treatment as shown by the DAS28-CRP and SDAI scores (Table 1).

**Angiogenic T cells**

At baseline, the percentage of Tang cells was significantly higher in RA patients as compared to HCs (14.6 ± 4.9% vs 10.0 ± 2.6%, respectively, \(p = 0.037\)). Interestingly, Tang cells significantly increased after 3 months of MTX treatment compared to baseline (22.9% ± 10.6% vs 14.6% ± 4.9%, \(p \leq 0.03\)) (Fig. 1A). In order to analyse the specific Tang cell phenotype involved in both subject cohorts, we subsequently investigated the expression of surface CD28 on Tang cells. At baseline, Tang in RA patients were characterized by a higher proportion of CD28null cells (69.4 ± 8.6% vs 47.8 ± 9.5%, respectively, \(p = 0.003\)) and lower CD28-positive (32.7 ± 8.0% vs 52.2 ± 9.5%, respectively, \(p = 0.006\)) cells compared with HCs, showing an imbalance towards a CD28null Tang cell population. Of interest, 3 months of MTX therapy restored a Tang cell phenotype similar to that of HCs (Fig. 1B).

**Endothelial activation markers**

In naïve RA patients, QRISK-2 score positively correlated with PMPs (rho = 0.657, \(p = 0.02\)), EPCs (rho = 0.673, \(p = 0.033\)) and CECs (rho = 0.569, \(p = 0.034\)). No significant correlation of QRISK-2 was found with Tang cells.

Subsequently, we evaluated the effect of MTX therapy on markers of endothelial dysfunction. At baseline, early RA patients displayed higher levels of sVCAM-1 compared to HCs (3973 ± 2410 vs 785 ± 283 ng/ml, respectively, \(p = 0.0188\)), which was significantly and markedly reduced after treatment with MTX (140 ± 49 ng/ml, \(p < 0.0001\)) (Fig. 1C). Similarly, at baseline, a significant higher concentration of circulating EMPs, a well-known marker of endothelial damage, was observed in early RA patients in comparison with HCs (583 ± 287/µl vs 122 ± 42/µl, respectively, \(p < 0.0001\)), and levels significantly reduced following MTX treatment (377 ± 277/µl, \(p = 0.015\)) (Fig. 1D).

Platelet CD40L expression was 7.63 ± 1.37% in HC, 16.08 ± 3.28% in early RA patients and 6.99 ± 1.15% in RA patients following a 3-month treatment with MTX.

---

**Fig. 1** Effects of methotrexate on biomarkers of endothelial dysfunction. Circulating Tang cells are more prevalent in early RA compared to HCs, and their number further increases following MTX treatment (A). Early RA patients show an altered balance of Tang cells in favour of a CD28nullphenotype which is restored following MTX treatment (B). In RA patients, 3-month MTX treatment restores sVCAM-1 (C), EMP (D), platelet CD40L (E) and EPC (G) to levels of HCs. CEC levels do not display significant differences (F). Data are shown as mean ± standard error. *\(p \leq 0.05\), **\(p \leq 0.01\), ***\(p \leq 0.001\), ****\(p \leq 0.0001\)
As expected, an opposed behaviour was observed for circulating EPCs, a marker of endothelial layer restoration. As shown in Fig. 1F, EPC levels were significantly lower in early RA compared to HCs at baseline (1.3 ± 0.5/µl vs 3.5 ± 0.7/µl, respectively, \( p < 0.0001 \)) and significantly increased to levels similar to HCs after MTX treatment (4.7 ± 2.4/µl, \( p = 0.0156 \)).

As far as CECs are concerned, we observed a trend towards higher levels of CECs in RA patients in comparison with HCs at baseline, although not statistically significant due to high variability (10.8 ± 3.9/µl vs 4.5 ± 1.6/µl, respectively, \( p = 0.077 \)). MTX treatment did not seem to exert a significant effect on CEC levels (Fig. 1G). To evaluate whether the observed effects were attributable to direct MTX action, to the reduction of disease activity following treatment or to a combination of the two elements, we performed a correlation analysis of the Δ variation of DAS28-CRP between baseline and 3 months follow-up and the Δ variation of biomarkers of interest. No significant correlation was found between the Δ disease activity and any of the variables analysed (Fig. 2).

Finally, in order to investigate whether the beneficial effects on endothelial function were maintained beyond 3 months of MTX treatment, a cohort of fifteen sex- and age-matched RA patients (mean age 51.5 ± 2.7 years) treated with MTX (mean dosage 12.3 ± 0.8 mg/week) for more than 6 months were enrolled. The mean MTX treatment duration in this cohort was 29 ± 12.5 months. As shown in Table 2, the levels of Tang cells, CD28-positive and CD28nullTang cells as well as of platelet CD40L and of markers of endothelial damage and restoration, including EMPs, EPCs and CECs, were similar in both groups, thus suggesting a stable, long-lasting beneficial effect of MTX on endothelial homeostasis.

**Discussion**

Endothelial dysfunction represents one of the earliest triggers of atherosclerosis development, and it greatly contributes to the increased CV risk in patients with chronic inflammatory rheumatic diseases [1]. Thus, identifying treatment strategies able to improve or reverse endothelial damage represents an important and largely unmet need in these patients. Experimental evidence suggests that MTX, beyond its favourable effects on lipid profile and insulin resistance, may act directly on the...


Markers of endothelial and platelet function do not significantly differ between RA patients treated with methotrexate for 3 months and patients with long-term treatment. Data are shown as mean ± standard error.

Shedding of endothelial MPs is a marker of damage, stress and dysfunction. Increased circulating EMPs have been previously reported in RA [39], and our study confirms these findings. On the contrary, circulating EPCs are bone marrow-derived cells that, along with Tang cells, are closely involved in endothelial repair [40, 41]. In line with this hypothesis, we found higher levels of EMPs and lower levels of EPCs in RA subjects compared to HCs. Of note, MTX treatment was able to restore both parameters to levels not different from those of HCs. In addition, we also confirmed a strong effect of MTX in reducing circulating levels of sVCAM-1, along with platelet CD40L, important markers of endothelial dysfunction [4, 28, 42, 43]. On the contrary, CEC concentration, whose levels are expected to be higher in inflammatory conditions, was not significantly different between RA and HCs due to very high variability in the former group. Nevertheless, MTX treatment did not seem to exert any significant effect on this cell population.

The effects of MTX on the endothelium and how MTX reduces chronic inflammation in patients with inflammatory diseases remain poorly understood. Although some reports suggest a potential detrimental effect on the endothelium [44], recent studies are in line with our findings [26] and suggest a potential, early, immune-modulatory effect of MTX on specific cellular subsets involved in endothelial homeostasis impairment. In particular, MTX reduces TNF-α-induced endothelial cell activation by modulation of VCAM-1, ICAM-1 and E-Selectin expression. It is also able to inhibit endothelial cell apoptosis, to promote their proliferation and to reduce the release of pro-inflammatory cytokines such as IL-6 and MCP-1 [31, 45].

Moreover, the demonstration that in our study the favourable effects on endothelial homeostasis seem to be at least partly independent of the reduction of systemic inflammation fits well with this hypothesis and confirms the results of recent in vitro and population-based studies [24, 33]. In fact, in a cohort of patients with the CV risk profile, MTX therapy did not reduce the levels of some inflammatory cytokines, such as TNFα, IL-1β and IL-6 [46]. This entails that multiple, still unexplored mechanisms of action beyond the anti-inflammatory mechanisms of the drug may contribute to the favourable effect of MTX on endothelial function [29–33]. Moreover, increased levels of platelet CD40L in RA have been reported [47, 48], and it has been proposed as a potential therapeutic target [49]. In an adjuvant arthritis rat model, MTX administration significantly reduced CD40L expression in the whole blood [50]. Given that platelet CD40L is a key player of endothelial dysfunction [10], it can be also hypothesized that MTX-induced platelet...
CD40L decrease contributes to the observed amelioration of endothelial dysfunction.

Our study has some limitations. First, the effects of MTX on endothelium were evaluated at 3-month therapy only. Although studies with longer duration are needed, we confirmed the rapid effect of MTX in halting the progression of atherosclerosis [28, 33]. These effects may be more pronounced in patients with early disease, as our cohort, since a chronic inflammatory condition may induce progressive irreversible endothelial damage and exhaustion of reparative mechanisms [14]. However, the demonstration of similar levels of endothelial markers of damage and repair between patients treated for 3 months and a subsequently included cohort of age- and sex-matched RA subjects treated for at least 6 months suggests a potential long-lasting beneficial effect.

Secondly, the present study does not allow us to ascertain whether these effects are due to MTX treatment, reduced disease activity or both. Although in our RA cohort, disease activity at 3 months was very variable ranging from remission to high, the low number of subjects did not allow a sub-group analysis. Indeed, the positive effects on the endothelium demonstrated in patients treated with TNFα inhibitors suggest that suppression of inflammation itself may prevent atherosclerosis progression [26, 32]. However, in our study, the protective effect on the endothelium was, at least in part, independent of change in disease activity, suggesting a specific direct action of MTX.

**Conclusions**

The results of the present study, although preliminary and to be confirmed by larger studies with longer follow-ups, confirm a rapid-onset beneficial effect of MTX on endothelial function in RA. In particular, we provide the first demonstration of its ability to restore a physiologic balance of circulating T cells, a population known to be directly involved in endothelial repair. This suggests that the rapid introduction of MTX therapy in RA patients with early disease may have additional CV benefits in RA patients independent of its role in controlling disease activity and systemic inflammation and further support its positive effects in reducing the risk of subsequent CV events in this population.

**Abbreviations**

CAM: Cell adhesion molecule; CDAI: Clinical disease activity index; CEC: Circulating endothelial cell; CRP: C-reactive protein; CV: Cardiovascular; DAS28: Disease Activity Score on 28 Joints; ELISA: Enzyme-linked immunosorbent assay; EMP: Endothelial microparticle; EPC: Endothelial progenitor cell; ESR: Erythrocyte sedimentation rate; EV: Extracellular vesicles; FITC: Fluorescein isothiocyanate; HC: Healthy control; MTX: Methotrexate; PGA: Patient’s global assessment; PHGA: Physician’s global assessment; pSS: Primary Sjögren’s syndrome; RA: Rheumatoid arthritis; SDAI: Simplified Disease Activity Index; SJC: Swollen joint count; SLE: Systemic lupus erythematosus; sVCAM: Soluble vascular cell adhesion molecule; Tang: Angiogenic T cell; TJC: Tender joint count; TNF: Tumour necrosis factor.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

AA, RG, PG and EB conceptualized and designed the work. AFB acquired the data. EP, OB, EF and SC performed the experiments. GC and EP performed the data analysis. GC, RG, PG and EB wrote the manuscript. All authors contributed to the data interpretation. The authors read and approved the final manuscript.

**Funding**

This study was not specifically funded.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

**Declarations**

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Rheumatology Unit, University of Perugia, Perugia, Italy. 2 Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. 3 Internal Medicine and Nephrology Unit, Department of Life, Health & Environmental Sciences, University of L’Aquila, L’Aquila, Italy.

**Received:** 12 August 2022   **Accepted:** 10 October 2022

**Published online:** 24 October 2022

**References**

1. Botts SR, Fish JE, Howe KL. Dysfunctional vascular endothelium as a driver of atherosclerosis: emerging insights into pathogenesis and treatment. Front Pharmacol. 2021;12:787541.
2. Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malinconico L, et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost. 2013;110:349–57.
3. Falcinelli E, Cosmi B, Filippini M, Petito E, Legnani C, Cini M, et al. Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. Thromb Res. 2017;157:20–2.
4. Falcinelli E, Petito E, Becattini C, De Robertis E, Paliani U, Sebastiani M, et al. Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients. J Infect. 2021;82:186–230.
5. Francisci D, Falcinelli E, Belfiori B, Petito E, Fierro T, Baldelli F, et al. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. AIDS Patient Care STDs. 2011;25:567–9.
6. Francisci D, Falcinelli E, Baroncelli S, Petito E, Cecchini E, Weiner LE, et al. Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers. Scand J Infect Dis. 2014;46:466–70.
7. Gresele P, Migliaccio R, Vedovati MC, Ruffatti A, Becattini C, Facco M, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009;123:444–51.
8. Hedjar AM, Stradner MH, Roessler A, Goswami N. Autoimmune rheumatic diseases and vascular function: the concept of autoimmune atherosclerosis. J Clin Med. 2021;10:4427.
9. Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C. Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res. 2018;70:1756–63.
10. Giannini S, Falcinelli E, Bury L, Guglielmini G, Rossi R, Momi S, et al. Interaction with damaged vascular wall in vivo in humans induces platelets to...
express CD40L resulting in endothelial activation with no effect of aspirin intake. Am J Physiol Heart Circ Physiol. 2011;300:H2072–2079.

11. André P, Nannuzzi-Alamo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896–9.

12. Cognasse F, Duchez AC, Audouz F, Ebermeyer T, Arthaud CA, Prier A, et al. Platelets as key factors in inflammation: focus on CD40L/CD40. Front Immunol. 2022;13:825892.

13. Lievens D, Zemecke A, Sejkous T, Soehnlein O, Beckers L, Munnix ICA, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood. 2010;116:4317–27.

14. Bartolini E, Alunno A, Tosti S, Curti B, Luccioli F, Santoboni G, et al. Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren’s syndrome: new markers of chronic endothelial damage? Rheumatol Oxf Engl. 2015;54:536–44.

15. Farinacci M, Krahm T, Dinh W, Volk H-D, Dünge H-D, Wagner J, et al. Circulating endothelial cells as biomarker for cardiovascular diseases. Res Pract Thromb Haemost. 2019;9:40–58.

16. Hur J, Yang H-M, Yoon C-H, Kim J-H, Hur J, et al. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation. 2007;116:1671–82.

17. Alunno A, Ibbá-Manneschi L, Bistoni O, Cipriani S, Topini F, Gerli R, et al. Angiogenic T cells in primary Sjögren’s syndrome: a double-edged sword? Clin Exp Rheumatol. 2019;37(Suppl 118):36–41.

18. López P, Rodríguez-Carrio J, Martínez-Zápico A, Caminal-Montero L, Suarez A. Senescent profile of angiogenic T cells from systemic lupus erythematosus patients. J Leukoc Biol. 2016;99:405–12.

19. Miao J, Qiu F, Li T, Zhao P, Zhang K, Lv M, et al. Circulating angiogenic T cells and their subpopulations in patients with systemic lupus erythematosus. Mediators Inflamm. 2016;2016:2842143.

20. Rodríguez-Carrio J, Alpern-López M, López P, Alonso-Castro S, Ballina-García FJ, Suárez A. Angiogenic T cells are decreased in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74:921–7.

21. de Boer SA, Reijrink M, Abdulahad WH, Hoekstra ES, Slart RHJA, Heerspink HJL, et al. A CD40L-expressing and neutrophil-dependent pathway for platelet activation in rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(Suppl 1):i57-60.

22. Habets KLL, Trouw LA, Levarht EWN, Korporaal SJA, Habets PAM, de Groot P, et al. Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs. 2000;2:5–14.

23. Thirunavukkarasu A, Guo M, Li L, Erre GL. Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence. Mediators Inflamm. 2017;2017:9632846.

24. Rui-Kai Z, Jian L. Effects of xinfeng capsules on expression of platelet granule microparticles in chronic kidney disease patients. Am J Chin Med. 2021;49:563–72.

25. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic diseases. Nat Rev Rheumatol. 2009;5:332–40.

26. Mangoni AA, Zimella A, Sotgia S, Cauu C, Piga M, Erre GL. Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence. Mediators Inflamm. 2017;2017:9632846.

27. Rui-Kai Z, Jian L. Effects of xinfeng capsules on expression of platelet granule microparticles in chronic kidney disease patients. Am J Chin Med. 2021;49:563–72.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.